Marina Mejias-Ortega
Overview
Explore the profile of Marina Mejias-Ortega including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Alberca J, de Rojas I, Sanchez-Mejias E, Garrido-Martin D, Gonzalez-Palma L, Jimenez S, et al.
J Alzheimers Dis
. 2024 Mar;
98(2):601-618.
PMID: 38427484
Background: Microglial dysfunction plays a causative role in Alzheimer's disease (AD) pathogenesis. Here we focus on a germline insertion/deletion variant mapping SIRPβ1, a surface receptor that triggers amyloid-β(Aβ) phagocytosis via...
2.
Kilian J, Mejias-Ortega M, Hsu H, Herman D, Vidal J, Arechavala R, et al.
Toxicol Sci
. 2023 Apr;
193(2):175-191.
PMID: 37074955
Exposure to traffic-related air pollution consisting of particulate matter (PM) is associated with cognitive decline leading to Alzheimer's disease (AD). In this study, we sought to examine the neurotoxic effects...
3.
Munoz-Castro C, Mejias-Ortega M, Sanchez-Mejias E, Navarro V, Trujillo-Estrada L, Jimenez S, et al.
Acta Neuropathol Commun
. 2023 Mar;
11(1):31.
PMID: 36855152
Microglia are brain-resident myeloid cells and play a major role in the innate immune responses of the CNS and the pathogenesis of Alzheimer's disease (AD). However, the contribution of nonparenchymal...
4.
Rodriguez-Ortiz C, Thorwald M, Rodriguez R, Mejias-Ortega M, Kieu Z, Maitra N, et al.
Clin Exp Pharmacol Physiol
. 2022 Nov;
50(3):228-237.
PMID: 36398458
Metabolic syndrome (MetS) is a rapidly increasing health concern during midlife and is an emerging risk factor for the development of neurodegenerative diseases, such as Alzheimer's disease (AD). While angiotensin...
5.
Sanchez-Varo R, Mejias-Ortega M, Fernandez-Valenzuela J, Nunez-Diaz C, Caceres-Palomo L, Vegas-Gomez L, et al.
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628216
Alzheimer's disease (AD) constitutes the most prominent form of dementia among elderly individuals worldwide. Disease modeling using murine transgenic mice was first initiated thanks to the discovery of heritable mutations...
6.
Sanchez-Varo R, Sanchez-Mejias E, Fernandez-Valenzuela J, De Castro V, Mejias-Ortega M, Gomez-Arboledas A, et al.
Front Neurosci
. 2021 Nov;
15:752594.
PMID: 34803589
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by initial memory impairments that progress to dementia. In this sense, synaptic dysfunction and loss have been established as the pathological...
7.
Garcia-Leon J, Caceres-Palomo L, Sanchez-Mejias E, Mejias-Ortega M, Nunez-Diaz C, Fernandez-Valenzuela J, et al.
Int J Mol Sci
. 2020 Sep;
21(18).
PMID: 32962164
Extracellular amyloid-beta deposition and intraneuronal Tau-laden neurofibrillary tangles are prime features of Alzheimer's disease (AD). The pathology of AD is very complex and still not fully understood, since different neural...
8.
Sanchez-Mejias E, Nunez-Diaz C, Sanchez-Varo R, Gomez-Arboledas A, Garcia-Leon J, Fernandez-Valenzuela J, et al.
Brain Pathol
. 2019 Sep;
30(2):345-363.
PMID: 31491047
Neuronal loss is the best neuropathological substrate that correlates with cortical atrophy and dementia in Alzheimer's disease (AD). Defective GABAergic neuronal functions may lead to cortical network hyperactivity and aberrant...